Ferriprox generic
Ferriprox is an oral solution owned by Chiesi. It contains the active ingredient deferiprone and was first authorized for market use on September 9, 2015. It has a total of 7 patents.
When will Ferriprox generic be available?
The generics of Ferriprox could be available after October 25, 2038. This is due to the expiry of the last patent, titled 'Delayed release deferiprone tablets and methods of using the same', filed under multiple patent numbers, including US10940115, US10780055, US10940116, US11357731, US11458103, and US11723874.
Ferriprox uses
Ferriprox is used as a method for treating transfusional iron overload. Its active ingredient, deferiprone, plays an effective role in this treatment.
Ferriprox patent expiration
Ferriprox has a total of 7 patents, none of which have expired. The last patent for Ferriprox, titled 'Delayed release deferiprone tablets and methods of using the same', is set to expire on October 25, 2038. This will allow the release of Ferriprox generics. Below are the details of the patent: